Simple is good: Yeast models of neurodegeneration

FEMS Yeast Research

Volumn 10, Issue 8, 2010, Pages 970-979

  Tenreiro, Sandra ^a   Outeiro, Tiago Fleming ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Drug discovery; Neurodegeneration; Protein misfolding; Yeast genetics

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; HEAT SHOCK PROTEIN 70; HUNTINGTIN; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL FEATURE; HUNTINGTON CHOREA; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SACCHAROMYCES CEREVISIAE; SUBSTANTIA NIGRA;

HUMANS; MODELS, NEUROLOGICAL; NEURODEGENERATIVE DISEASES; SACCHAROMYCES CEREVISIAE;

EUKARYOTA; FUNGI; SACCHAROMYCES CEREVISIAE; SACCHAROMYCETALES;

EID: 78349294528     PISSN: 15671356     EISSN: 15671364     Source Type: Journal    
DOI: 10.1111/j.1567-1364.2010.00649.x     Document Type: Review

References (97)

1. Anderson JP, Walker DE, Goldstein JM et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281: 29739-29752.
2. Arrasate M, Mitra S, Schweitzer ES, Segal MR & Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810.
3. Bell PJ, Davies IW & Attfield PV (1999) Facilitating functional analysis of the Saccharomyces cerevisiae genome using an EGFP-based promoter library and flow cytometry. Yeast 15: 1747-1759.
4. Bodner RA, Outeiro TF, Altmann S et al. (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. P Natl Acad Sci USA 103: 4246-4251.
5. Chartier-Harlin MC, Kachergus J, Roumier C et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
6. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT & Feany MB (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119: 3257-3265.
7. Chopra V, Fox JH, Lieberman G et al. (2007) A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. P Natl Acad Sci USA 104: 16685-16689.
8. Christie KR, Hong EL & Cherry JM (2009) Functional annotations for the Saccharomyces cerevisiae genome: the knowns and the known unknowns. Trends Microbiol 17: 286-294.
9. Cooper AA, Gitler AD, Cashikar A et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313: 324-328.
10. Cummings CJ, Sun Y, Opal P et al. (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10: 1511-1518.
11. Davies SW, Turmaine M, Cozens BA et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548.
12. Dehay B & Bertolotti A (2006) Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem 281: 35608-35615.
13. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP & Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
14. Dixon C, Mathias N, Zweig RM, Davis DA & Gross DS (2005) Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 170: 47-59.
15. Duennwald ML, Jagadish S, Muchowski PJ & Lindquist S (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. P Natl Acad Sci USA 103: 11045-11050.
16. Duyao M, Ambrose C, Myers R et al. (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4: 387-392.
17. Ehrnhoefer DE, Duennwald M, Markovic P et al. (2006) Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 15: 2743-2751.
18. Feany MB & Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404: 394-398.
19. Fields S & Johnston M (2005) Cell biology. Whither model organism research? Science 307: 1885-1886.
20. Fleming J, Outeiro TF, Slack M, Lindquist SL & Bulawa CE (2008) Detection of compounds that rescue Rab1-synuclein toxicity. Method Enzymol 439: 339-351.
21. Flower TR, Chesnokova LS, Froelich CA, Dixon C & Witt SN (2005) Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol 351: 1081-1100.
22. Flower TR, Clark-Dixon C, Metoyer C, Yang H, Shi R, Zhang Z & Witt SN (2007) YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. J Cell Biol 177: 1091-1104.
23. Franssens V, Boelen E, Anandhakumar J, Vanhelmont T, Buttner S & Winderickx J (2010) Yeast unfolds the road map toward alpha-synuclein-induced cell death. Cell Death Differ 17: 746-753.
24. Gasser T (2001) Genetics of Parkinson's disease. J Neurol 248: 833-840.
25. Ghaemmaghami S, Huh WK, Bower K et al. (2003) Global analysis of protein expression in yeast. Nature 425: 737-741.
26. Giorgini F, Guidetti P, Nguyen Q, Bennett SC & Muchowski PJ (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37: 526-531.
27. Gitler AD (2008) Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals 16: 52-62.
28. Gitler AD, Bevis BJ, Shorter J et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. P Natl Acad Sci USA 105: 145-150.
29. Gitler AD, Chesi A, Geddie ML et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41: 308-315.
30. Goffeau A, Barrell BG, Bussey H et al. (1996) Life with 6000 genes. Science 274: 546-563.
31. Gosavi N, Lee HJ, Lee JS, Patel S & Lee SJ (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 277: 48984-48992.
32. Greenfield JP, Xu H, Greengard P, Gandy S & Seeger M (1999) Generation of the amyloid-beta peptide N terminus in Saccharomyces cerevisiae expressing human Alzheimer's amyloid-beta precursor protein. J Biol Chem 274: 33843-33846.
33. Griffioen G, Duhamel H, Van Damme N et al. (2006) A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta 1762: 312-318.
34. Hatano T, Kubo S, Sato S & Hattori N (2009) Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem 111: 1075-1093.
35. Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM & Fields S (2001) Altered transcription in yeast expressing expanded polyglutamine. P Natl Acad Sci USA 98: 13201-13206.
36. Huh WK, Falvo JV, Gerke LC, Carroll AS, Howson RW, Weissman JS & O'Shea EK (2003) Global analysis of protein localization in budding yeast. Nature 425: 686-691.
37. Ibanez P, Bonnet AM, Debarges B et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364: 1169-1171.
38. Imarisio S, Carmichael J, Korolchuk V et al. (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412: 191-209.
39. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF & Hyman BT (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropath Exp Neur 57: 334-337.
40. Jones GM, Stalker J, Humphray S et al. (2008) A systematic library for comprehensive overexpression screens in Saccharomyces cerevisiae. Nat Methods 5: 239-241.
41. Joyner PM, Matheke RM, Smith LM & Cichewicz RH (2010) Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice. J Proteome Res 9: 404-412.
42. Kim S, Nollen EA, Kitagawa K, Bindokas VP & Morimoto RI (2002) Polyglutamine protein aggregates are dynamic. Nat Cell Biol 4: 826-831.
43. Kritzer JA, Hamamichi S, McCaffery JM et al. (2009) Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol 5: 655-663.
44. Krobitsch S & Lindquist S (2000) Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. P Natl Acad Sci USA 97: 1589-1594.
45. Kruger R, Kuhn W, Muller T et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
46. Kumar A, Cheung KH, Tosches N, Masiar P, Liu Y, Miller P & Snyder M (2002) The TRIPLES database: a community resource for yeast molecular biology. Nucleic Acids Res 30: 73-75.
47. Lakso M, Vartiainen S, Moilanen AM et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86: 165-172.
48. Leitch JM, Yick PJ & Culotta VC (2009) The right to choose: multiple pathways for activating copper, zinc superoxide dismutase. J Biol Chem 284: 24679-24683.
49. Liang J, Clark-Dixon C, Wang S et al. (2008) Novel suppressors of alpha-synuclein toxicity identified using yeast. Hum Mol Genet 17: 3784-3795.
50. Luo S, Vacher C, Davies JE & Rubinsztein DC (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 169: 647-656.
51. Maetzler W, Liepelt I & Berg D (2009) Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 8: 1158-1171.
52. Maji SK, Perrin MH, Sawaya MR et al. (2009) Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325: 328-332.
53. Martin JB & Gusella JF (1986) Huntington's disease. Pathogenesis and management. New Engl J Med 315: 1267-1276.
54. Martzen MR, McCraith SM, Spinelli SL, Torres FM, Fields S, Grayhack EJ & Phizicky EM (1999) A biochemical genomics approach for identifying genes by the activity of their products. Science 286: 1153-1155.
55. Masliah E, Rockenstein E, Veinbergs I et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269.
56. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO & Sherman MY (2002) Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 157: 997-1004.
57. Meriin AB, Zhang X, Miliaras NB et al. (2003) Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Mol Cell Biol 23: 7554-7565.
58. Meriin AB, Zhang X, Alexandrov IM, Salnikova AB, Ter-Avanesian MD, Chernoff YO & Sherman MY (2007) Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains. FASEB J 21: 1915-1925.
59. Mnaimneh S, Davierwala AP, Haynes J et al. (2004) Exploration of essential gene functions via titratable promoter alleles. Cell 118: 31-44.
60. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK & Hartl FU (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. P Natl Acad Sci USA 97: 7841-7846.
61. Muchowski PJ, Ning K, D'Souza-Schorey C & Fields S (2002) Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. P Natl Acad Sci USA 99: 727-732.
62. Outeiro TF & Lindquist S (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302: 1772-1775.
63. Outeiro TF, Kontopoulos E, Altmann SM et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317: 516-519.
64. Polyakova O, Dear D, Stern I et al. (2009) Proteolysis of prion protein by cathepsin S generates a soluble beta-structured intermediate oligomeric form, with potential implications for neurotoxic mechanisms. Eur Biophys J 38: 209-218.
65. Polymeropoulos MH, Lavedan C, Leroy E et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
66. Puccio H & Koenig M (2000) Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 9: 887-892.
67. Rockabrand E, Slepko N, Pantalone A et al. (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16: 61-77.
68. Rubinsztein DC, Leggo J, Coles R et al. (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59: 16-22.
69. Schilling B, Gafni J, Torcassi C et al. (2006) Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 281: 23686-23697.
70. Schwarcz R (2004) The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4: 12-17.
71. Sharma N, Brandis KA, Herrera SK, Johnson BE, Vaidya T, Shrestha R & Debburman SK (2006) Alpha-synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J Mol Neurosci 28: 161-178.
72. Singleton AB, Farrer M, Johnson J et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302: 841.
73. Smith MG & Snyder M (2006) Yeast as a model for human disease. Curr Protoc Hum Genet supplement 48, 15.6.1-15.6.8.
74. Sokolov S, Pozniakovsky A, Bocharova N, Knorre D & Severin F (2006) Expression of an expanded polyglutamine domain in yeast causes death with apoptotic markers. Biochim Biophys Acta 1757: 660-666.
75. Solans A, Zambrano A, Rodriguez M & Barrientos A (2006) Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet 15: 3063-3081.
76. Soper JH, Roy S, Stieber A et al. (2008) {alpha}-Synuclein induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell 19: 1093-1103.
77. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R & Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
78. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL & Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251: 205-208.
79. Su LJ, Auluck PK, Outeiro TF et al. (2010) Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 3: 194-208.
80. Sugiyama M, Yamagishi K, Kim YH, Kaneko Y, Nishizawa M & Harashima S (2009) Advances in molecular methods to alter chromosomes and genome in the yeast Saccharomyces cerevisiae. Appl Microbiol Biot 84: 1045-1052.
81. Suter B, Auerbach D & Stagljar I (2006) Yeast-based functional genomics and proteomics technologies: the first 15 years and beyond. Biotechniques 40: 625-644.
82. Tam S, Geller R, Spiess C & Frydman J (2006) The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 8: 1155-1162.
83. Telenius H, Kremer HP, Theilmann J et al. (1993) Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 2: 1535-1540.
84. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
85. Vamvaca K, Volles MJ & Lansbury PT Jr (2009) The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol 389: 413-424.
86. Volles MJ & Lansbury PT Jr (2007) Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 366: 1510-1522.
87. Wacker JL, Huang SY, Steele AD et al. (2009) Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J Neurosci 29: 9104-9114.
88. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR & Hayden MR (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40: 121-127.
89. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL & Bonini NM (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23: 425-428.
90. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL & Muchowski PJ (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302: 1769-1772.
91. Winzeler EA, Shoemaker DD, Astromoff A et al. (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285: 901-906.
92. Yeger-Lotem E, Riva L, Su LJ et al. (2009) Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet 41: 316-323.
93. Zabrocki P, Pellens K, Vanhelmont T et al. (2005) Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast. FEBS J 272: 1386-1400.
94. Zabrocki P, Bastiaens I, Delay C et al. (2008) Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim Biophys Acta 1783: 1767-1780.
95. Zarranz JJ, Alegre J, Gomez-Esteban JC et al. (2004) The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
96. Zhang X, Smith DL, Meriin AB et al. (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. P Natl Acad Sci USA 102: 892-897.
97. Zhou W, Hurlbert MS, Schaack J, Prasad KN & Freed CR (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res 866: 33-43.